Canrenone
Canrenone structure
|
Common Name | Canrenone | ||
|---|---|---|---|---|
| CAS Number | 976-71-6 | Molecular Weight | 340.456 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 541.1±50.0 °C at 760 mmHg | |
| Molecular Formula | C22H28O3 | Melting Point | 158-160ºC | |
| MSDS | Chinese USA | Flash Point | 237.6±30.2 °C | |
| Symbol |
GHS08, GHS09 |
Signal Word | Warning | |
|
Aldosterone receptor blockers spironolactone and canrenone: two multivalent drugs.
Expert Opin. Pharmacother. 15(7) , 909-12, (2014) Canrenone is a derivative of spironolactone with lower antiandrogen activity. The drug is used only in few countries and can block all the side effects of aldosterone (ALDO). The drug is effective even in the presence of normal concentrations of ALDO. Mineral... |
|
|
Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.
Br. J. Clin. Pharmacol. 75(5) , 1202-12, (2013) Aldosterone antagonists (AldoAs) have been used to treat severe chronic heart failure (CHF). There is uncertainty regarding the efficacy of using AldoAs in mild to moderate CHF with New York Heart Association (NYHA) classifications of I to II. This study summ... |
|
|
The effects of canrenone on inflammatory markers in patients with metabolic syndrome.
Ann. Med. 47(1) , 47-52, (2015) To evaluate the effects of canrenone compared to placebo on blood pressure control, some non-conventional biomarkers in cardiovascular stratification, and on metalloproteinases in patients affected by metabolic syndrome.A total of 156 Caucasian patients were ... |
|
|
Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients.
Br. J. Clin. Pharmacol. 74(5) , 864-72, (2012) Little is known about the pharmacokinetics of potassium canrenoate/canrenone in paediatric patientsA population pharmacokinetic model has been developed to evaluate the pharmacokinetics of canrenone in paediatric patients who received potassium canrenoate as ... |
|
|
Effect of spironolactone, potassium canrenoate and their common metabolite canrenone on serum digoxin measurement by digoxin III, a new digoxin immunoassay.
Ther. Drug Monit. 30(6) , 744-7, (2008) Spironolactone and potassium canrenoate (aldosterone antagonist diuretics) are often used with digoxin in clinical practice. It has been well documented in the literature that spironolactone, potassium canrenoate, and their common metabolite canrenone cross-r... |
|
|
Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
J. Clin. Lab Anal. 24(6) , 413-7, (2010) Spironolactone, a potassium sparing diuretic metabolized to canrenone, is often used with digoxin to treat various conditions including congestive heart failure. Potassium canrenoate is a similar drug that is also metabolized to canrenone. Due to reported int... |
|
|
Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.
J. Clin. Lab Anal. 26(3) , 143-7, (2012) Spironolactone, a potassium-sparing diuretic metabolized to canrenone is often used with digoxin to treat various conditions including congestive heart failure. Potassium canrenoate is a similar drug, which is also metabolized to canrenone. Due to reported bo... |
|
|
Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common metabolite canrenone.
Ther. Drug Monit. 33(1) , 128-31, (2011) Spironolactone, which is metabolized to canrenone, is often used in combination with digoxin. Potassium canrenoate is a similar drug that is also metabolized to canrenone. As a result of reported interference of spironolactone, potassium canrenoate, and their... |
|
|
Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction.
Drug Metab. Dispos. 38(7) , 1011-4, (2010) Elevated plasma concentrations of aldosterone (ALDO) are observed in patients treated with spironolactone. Because ALDO is eliminated via UGT2B7-catalyzed 18beta-glucuronidation, this study aimed to determine whether spironolactone and its primary metabolites... |
|
|
Polyuric-polydipsic syndrome in a pediatric case of non-glucocorticoid remediable familial hyperaldosteronism.
Endocr. J. 59(6) , 497-502, (2012) Familial hyperaldosteronism (FH) encompasses 3 types of autosomal dominant hyperaldosteronisms leading to inheritable hypertension. FH type II (FH-II), undistinguishable from sporadic hyperaldosteronism, represents the most frequent cause of inheritable hyper... |